![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Topline Results from a 12-Week Phase 2a Trial
(DUET) Evaluating TERN-501, a Highly Selective Thyroid Hormone Receptor (THR) β Agonist, Either as Monotherapy or in Combination with TERN-101, a Nonsteroidal Farnesoid X Receptor (FXR) Agonist, Demonstrated Significant Reductions in MR-Based Liver Fat Content and Fibroinflammation in Patients with Presumed MASH
|
|
|
AASLD 2023 nov 10-14
listen to live session
https://www.aasld.org/the-liver-meeting
![1120231](../images/112023/112023-18/1120231.gif)
![1120232](../images/112023/112023-18/1120232.gif)
![1120233](../images/112023/112023-18/1120233.gif)
![1120234](../images/112023/112023-18/1120234.gif)
MRI-PDFF is a quantitative imaging biomarker that enables accurate, repeatable and reproducible quantitative assessment of liver fat over the entire liver (9, 11-14). Thus, MRI-PDFF is emerging as one of the leading non-invasive quantitative biomarkers suitable as a surrogate to liver biopsy for assessing treatment response in a subset of NASH trials.
![1120235](../images/112023/112023-18/1120235.gif)
![1120236](../images/112023/112023-18/1120236.gif)
![1120237](../images/112023/112023-18/1120237.gif)
![1120238](../images/112023/112023-18/1120238.gif)
![1120239](../images/112023/112023-18/1120239.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|